Under the terms of this agreement, New England Biolabs (NEB) will also manufacture Solexa’s proprietary sequencing-by-synthesis polymerase.
Solexa claims that its Genome Analysis System will enable researchers to tackle a broad range of applications, including whole-genome and candidate region sequencing, digital expression profiling, and small RNA discovery and analysis.
“Having a strong relationship with a leader in next-generation sequencing technologies is of great value to NEB, allowing us to contribute to an area which has the potential to change both biological research and the practice of human medicine,” commented Dr Fiona Stewart, business development manager at NEB. “We are very pleased that our expertise in enzyme technology and reagent manufacturing has been recognized by Solexa.”
Financial terms of the supply agreement were not disclosed.